Analysis of outcomes of nab-paclitaxel compared to other taxanes in early breast cancer: A study revealing the critical role of calendar-time bias in real-world drug comparisons.
文献摘要
Objective To compare long-term survival outcomes of nab-paclitaxel versus other taxanes in early breast cancer and to evaluate the impact of calendar-time bias in real-world studies. Methods We enrolled 9217 early invasive breast cancer patients (2007-2024) divided into nab-paclitaxel (n = 3860) and other taxanes (n = 5357) groups. The primary analysis employed three separate Cox models: Model 1 (unadjusted for time), Model 2 (adjusted for year of diagnosis), and Model 3 (adjusted for COVID-19 periods). Sensitivity analyses included propensity score matching, overlap-period restriction, restricted cubic splines, calendar-period stratification, and multiple imputation. Endpoints were overall survival (OS), disease-free survival (DFS), and distant metastasis-free survival (DMFS). Results Median diagnosis year was 2021 for nab-paclitaxel vs. 2015 for other taxanes (P Conclusion After adjusting for calendar-time bias using categorical year adjustment, no significant differences in long-term survival were observed between nab-paclitaxel and other taxanes in patients with early breast cancer. This study highlights the critical role of calendar-time bias in long-term real-world comparative studies, and provides important methodological guidance for future similar research.